Infusion-related reactions and premedication patterns in ublituximab-treated multiple sclerosis patients: a multicenter real-world study - Report - MDSpire
Advertisement
Infusion-related reactions and premedication patterns in ublituximab-treated multiple sclerosis patients: a multicenter real-world study
Clinical Report: Infusion-Related Reactions in MS Patients Treated with Ublituximab
Overview
This study characterizes infusion-related reactions (IRRs) in multiple sclerosis patients treated with ublituximab, revealing that 34.8% experienced IRRs, all of which were mild to moderate. The acetaminophen dose was significantly associated with IRR occurrence.
Background
Ublituximab is a novel anti-CD20 monoclonal antibody approved for treating multiple sclerosis, known for its efficacy in reducing relapse rates. However, it carries a notable risk of infusion-related reactions.
Data Highlights
Parameter
Value
Patients with IRRs
34.8% (n = 31)
Significant association with IRR
Acetaminophen dose (p = 0.006)
Severity of IRRs
Mild to moderate
Key Findings
34.8% of ublituximab-treated patients experienced infusion-related reactions (IRRs).
All observed IRRs were classified as mild to moderate in severity.
The acetaminophen dose was significantly associated with the occurrence of IRRs (p = 0.006).
Timing of IRRs varied significantly across certain corticosteroid and antihistamine categories.
No independent predictors of IRRs were identified in this study.
Clinical Implications
Clinicians should be aware of the significant incidence of mild to moderate IRRs in patients receiving ublituximab.
Conclusion
The study highlights the prevalence of IRRs in ublituximab-treated MS patients.
by Anas Z. Nourelden, Parker R. Scott, Sam I. Hooshmand, Izabela Mazur, Felicia Mada, Tesiley Ash, Nidhi Patel, Jacob Rube, Kalyan Yarraguntla, Carey Deluca, Patti Yager-Stone, Ryan Havens, Mitchell Wallin, Anza B. Memon
